It's Time to Move Forward

NanoString Technologies is committed to prognostic technology, helping improve cancer care for patients around the world.

The Prosigna Patient Support Program (PPSP) is designed to help breast cancer patients gain access to the important information which can be obtained from the Prosigna Prognostic Breast Cancer Gene Signature. The program includes an array of services to meet the needs of patients and health care providers.

Enroll your patients today using the online form or call 855-4-PROSIGNA to speak to a program counselor.

For more information, download the patient brochure

Patient assistance may help your patient obtain the important prognostic information she needs (based on program eligibility). To get started, call 855-4-PROSIGNA to speak to a program counselor.

PPSP will help determine your patient’s benefits and coverage through a benefits investigation and/or by obtaining prior authorization.

Benefits Investigation (BI): Resource counselors will conduct a benefits investigation to determine the payor’s requirements or extent of coverage for the Prosigna Assay. A BI can produce one of three outcomes:

  1. Positive Coverage
  2. Prior Authorization (PA)
  3. Coverage is denied/unavailable

Prior Authorization (PA): Our resource counselors will help you determine if a PA is needed and will help complete PA forms (if applicable). If coverage is not available, our counselors will help determine next steps.

Our program counselors will help navigate through denials and appeals and also offer billing/coding information.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.